Test different dosing schedules for two immunotherapy drugs
Part of Cancer clinical trials.
This early trial compares how often two immune system medicines—nivolumab and pembrolizumab—are given for advanced or metastatic cancers. It aims to see which dosing interval is workable and safe for people needing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a locally advanced or metastatic cancer where your doctor recommends nivolumab or pembrolizumab
- You are 18 years old or older
- Your cancer can be measured on scans to track response
- You have not previously received immune checkpoint drugs like nivolumab or pembrolizumab
- Your planned treatment will not include ipilimumab or any anti-CTLA-4 antibody together with nivolumab or pembrolizumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This study tests a new way of giving a combination of two immunotherapy drugs (ipilimumab and nivolumab) for advanced melanoma. The drugs are given either into a vein or into the skin, to see if the skin injection works as well and causes fewer side effects.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.